Study Details

Open

Clinical Trial on Hidradenitis Suppurativa

This is a clinical research study to learn more about a drug being developed to treat Hidradenitis Suppurativa. We want to learn more about how this study drug affects those with Hidradenitis Suppurativa.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

At each visit, you will meet with a member of the study team. You'll answer some questions about your health and medications and have a physical exam. The study will also involve blood draws and willingness to take the study medication regularly. You would have a 66% chance of receiving INCB054707/povorcitinib (2:1). The first 12 weeks you could be randomized into 1 of 3 groups. • One group receives INCB054707/povorcitinib at a lower dose of 45mg; • One group receives INCB054707/povorcitinib at a higher dose of 75mg; • One group receives placebo, which looks like the same tablet, but doesn't contain active drug After the 1st 12 weeks, you will receive either lower dose or the higher dose of INCB054707/povorcitinib for 10.5 months.

Incentives

Information provided upon request, study medication

In-person visits:
15

Total length of participation:
14 months

Looking for Specific Volunteers

Able to participate:

Are able to comprehend and willing to sign a written ICF for the study.
Diagnosis of moderate to severe HS for at least 3 months
Documented history of inadequate response to at least a 3-month course of at least 1 conventional systemic therapy (oral antibiotic or biologic drug) for HS
Agree to stop all topical and systemic antibiotics for HS, diluted bleach baths, and antiseptic washes containing chlorhexidine or benzoyl peroxide
Willing to use a form of birth control during your participation through 90 days after the last dose

Not eligible if:

Have thrombocytopenia, coagulopathy, or platelet dysfunction
Have had venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, heart failure, cerebrovascular accident, myocardial infarction
Diagnosis of other significant cardiovascular diseases
Recipient of an organ transplant that requires continued immunosuppression
Chronic or recurrent infectious disease

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Dermatology Clinical Trials Unit (DCTU)
UNC Dermatology and Skin Cancer Center at Southern Village
410 Market St Ste 362, Chapel Hill, NC 27516, USA

Additional Study Information

Principal Investigator

Chris Sayed
Dermatology - Adult

Study Type

Clinical or Medical
Interventional

Study Topics

Skin, Hair, and Nails

IRB Number

22-3258

ClinicalTrials.gov

NCT05620823